First Accuray CyberKnife® M6™ System Installed in Missouri at Mercy Hospital St. Louis
SRS and SBRT are non-invasive forms of radiation therapy that use high doses of very targeted radiation to destroy tumors, in just a few treatment sessions (1 to 5). SRS is commonly used to treat conditions within the brain and spine, while SBRT is used for those tumors located outside these areas. The CyberKnife M6 System is equipped with sophisticated functionality that will streamline the creation of personalized treatment plans and reduce the time to deliver radiation treatments, enabling the Mercy St. Louis team to offer precision SRS and SBRT treatments to more patients each day.
The
"The CyberKnife M6 is really an ideal system for the hospital and for our patients. The system combines sub-millimeter accuracy with real-time image guidance, enabling our team to effectively treat almost any part of the body requiring radiation therapy," said
Click here to see how the CyberKnife System treats brain tumors and here to see the system treat prostate cancer.
"We congratulate the
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About the CyberKnife System
The CyberKnife System is the only robotic radiosurgery system that offers highly precise, non-surgical treatment for tumors and lesions anywhere in the body—including the brain, breast, kidney, liver, lung, pancreas, prostate and spine. The CyberKnife System tracks and automatically adjusts for tumor or patient movement during treatment, delivering the radiation dose directly to the target with sub-millimeter precision. Synchrony® motion tracking and correction technology expands on the CyberKnife System's unique motion synchronization capabilities to provide additional precision when treating tumors that move with respiration. The high level of accuracy in dose delivery made possible by the system gives clinical teams the confidence to deliver state-of-the-art treatments for a wide range of cancers and functional disorders, without sacrificing patients' quality of life.
About
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the anticipated installation of Radixact Systems at other Mercy hospitals, clinical applications, clinical results, patient experiences, patient outcomes and the company's ability to continue to penetrate the global radiation therapy market. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contacts
Public Relations Director,
+1 (408) 789-4426
bkaplan@accuray.com
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/first-accuray-cyberknife-m6-system-installed-in-missouri-at-mercy-hospital-st-louis-301010448.html
SOURCE